

ASX Announcement

29 April 2009

Appendix 4C Quarterly Report

Resonance Health Limited (ASX: RHT) today released its third quarter cash flow report. The quarter represented the 6th consecutive profitable quarter for the Company which is on track to delivery of a first full year profit.

Due to a significant customer payment due in March but received in April, a small negative cash flow of \$77,000 was reported. A positive cash flow would otherwise have been the result for the quarter.

All other income and expenditure was as expected, including reduced interest income as a result of lowering interest rates. Expenditure on consultants has increased with the engagement of a marketing representative in the UK and technical consultants supporting R&D projects focused on improvements to FerriScan and the development of an MRI test for liver fibrosis. Cash on hand at the end of the quarter was \$2.6m being \$355,000 more than the same time last year.

Resonance Health's core product, FerriScan[®], continues to be established as an innovative and leading product in the market for assessing iron overload, and is well known in our established markets.

Resonance Health continues to invest for the future with increased expenditure on research and development, clinical studies and marketing. FerriScan sales are expected to grow and together with a cash surplus and nil borrowings, management and directors are confident of the company's ability to grow and deliver a positive return to shareholders.

The Company is mindful of the need to exercise prudent financial management in the current economic environment, and maintaining cash reserves is a priority.

For more information about Resonance Health, visit our web site www.resonancehealth.com or contact:

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@ferriscan.com

Eva O'Malley
Company Secretary
T: +61 8 9286 5300
E: evao@ferriscan.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced medical technology for the analysis of medical images. It's patented technology FerriScan[®], provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. Initial commercialisation of FerriScan[®] has focused on pharmaceutical companies developing drug therapies to treat iron overload, and is now being extended to the broader international clinical community.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

31 March 2009

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date \$A'000
1.1 Receipts from customers	424	1,529
Other Receipts	-	-
1.2 Payments for		
(a) staff costs	(207)	(693)
(b) advertising and marketing	(24)	(60)
(c) research and development	(96)	(137)
(d) leased assets	-	-
(e) other working capital	(45)	(152)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	27	111
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/received	-	-
1.7 Other Payments		
(a) consulting & professional services	(107)	(200)
(b) statutory & compliance	(24)	(105)
(c) travel	(5)	(26)
Net operating cash flows	(57)	267

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter	Year to date
		\$A'000	\$A'000
1.8	Net operating cash flows (carried forward)	(57)	267
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(20)	(27)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses (item 5)	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (Cash introduced on acquisition of controlled entity)	-	-
	Net investing cash flows	(20)	(27)
1.14	Total operating and investing cash flows	(77)	240
Cash flows related to financing activities			
1.15	Proceeds from issues of shares, options, etc.	-	-
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	-
1.18	Repayment of borrowings	-	-
1.19	Dividends paid	-	-
1.20	Other (costs of capital raising)	-	-
	Net financing cash flows	-	-
	Net increase (decrease) in cash held	(77)	240
1.21	Cash at beginning of quarter/year to date	2,699	2,382
1.22	Exchange rate adjustments to item 1.20		
1.23	Cash at end of quarter	2,622	2,622

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	80
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

\$12k – Directors fees \$68k – Consulting fees

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	-	-
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	53	88
4.2 Deposits at call	419	461
4.3 Bank overdraft		
4.4 Other (provide details) - 30 day term deposit	2,150	2,150
Total: cash at end of quarter (item 1.22)	2,622	2,699

Acquisitions and disposals of business entities

	Acquisitions <i>(Item 1.9(a))</i>	Disposals <i>(Item 1.10(a))</i>
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Eva O'Malley
Company Secretary

+ See chapter 19 for defined terms.